North America Non Hodgkin Lymphoma Diagnostics Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2024 –2030 |
 Taille du marché (année de référence) |
|
 Taille du marché (année de prévision) |
|
 TCAC |
% |
| Principaux acteurs du marché |
>Marché nord-américain du diagnostic du lymphome non hodgkinien, par type de test (imagerie, biopsie, immunohistochimie, biomarqueur, test génétique , cytogénétique, ponction lombaire, test sanguin, cytochimie et autres), stade du cancer (stade IV, stade III, stade II, stade I et stade 0), type de tumeur (lymphomes agressifs et lymphomes indolents), produit (produits basés sur des instruments, produits basés sur des plateformes, kits et réactifs et autres consommables), technologie (hybridation in situ fluorescente, séquençage de nouvelle génération, fluoroimmuno-essai, hybridation génomique comparative, immunohistochimie et autres), application (dépistage, diagnostic et prédiction, pronostic et recherche), utilisateur final (hôpitaux, centres de diagnostic, centres de recherche sur le cancer, instituts universitaires, centres de chirurgie ambulatoire et autres), canal de distribution (appel d'offres direct, vente au détail et autres) - Industrie Tendances et prévisions jusqu'en 2030.
Analyse et perspectives du marché du diagnostic du lymphome non hodgkinien en Amérique du Nord
La sensibilisation croissante au lymphome non hodgkinien en Amérique du Nord a accru la demande sur le marché. L'augmentation des dépenses de santé pour de meilleurs services de santé contribue également à la croissance du marché. Les principaux acteurs du marché se concentrent sur le lancement et l'approbation de divers services au cours de cette période cruciale. En outre, l'augmentation des processus et techniques de diagnostic améliorés contribue également à la demande croissante de tests de diagnostic du lymphome non hodgkinien.
Le marché nord-américain du diagnostic du lymphome non hodgkinien devrait croître au cours de l'année de prévision en raison de l'augmentation du nombre d'acteurs sur le marché et de la disponibilité de services avancés. Parallèlement à cela, les fabricants sont engagés dans des activités de R&D pour lancer de nouveaux services sur le marché. L'augmentation des recherches dans le domaine du diagnostic et du développement du lymphome non hodgkinien stimule encore la croissance du marché. Cependant, les difficultés liées aux techniques de dépistage du lymphome non hodgkinien pourraient entraver la croissance du marché nord-américain du diagnostic du lymphome non hodgkinien au cours de la période de prévision.
L'augmentation des dépenses de santé consacrées au diagnostic et au traitement du cancer devrait offrir au marché des opportunités d'améliorer le traitement. Cependant, le coût élevé des tests et les réglementations et normes strictes pour l'approbation et la commercialisation des produits de diagnostic du cancer peuvent constituer un obstacle à la croissance du marché.
Le marché nord-américain du diagnostic du lymphome non hodgkinien est favorable et vise à réduire la progression de la maladie. Data Bridge Market Research analyse que le marché nord-américain du diagnostic du lymphome non hodgkinien connaîtra une croissance de 9,1 % au cours de la période de prévision de 2023 à 2030.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Années historiques |
2021 (personnalisable de 2015 à 2020) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD et prix en USD |
|
Segments couverts |
Test Type (Imaging, Biopsy, Immunohistochemistry, Biomarker, Genetic Test, Cytogenetics, Lumbar Puncture, Blood Test, Cytochemistry And Others), Cancer Stage (Stage IV, Stage III, Stage II, Stage I, and Stage 0), Tumor Type (Aggressive Lymphomas, and Indolent Lymphomas), Product (Instrument Based Products, Platform Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) |
|
Countries Covered |
U.S., Canada, Mexico |
|
Market Players Covered |
CANON MEDICAL SYSTEMS CORPORATION (Tochigi Prefecture, Japan), Koninklijke Philips N.V.(Amsterdam, Netherland), Siemens Healthcare GmbH (Erlangen, Germany), Danaher (Washington U.S.), Bio-Rad Laboratories, Inc (California, U.S.), General Electric Company (Massachusetts, U.S.), Sysmex Corporation (Hyogo, Japan), Grail (California, U.S.), F. Hoffmann-La Roche (Basel, Switzerland), Neusoft Corporation (Shenyang, China), Agilent Technologies, Inc. (California, U.S.), NeoGenomics Laboratories(Florida, U.S), Hologic, Inc(Massachusetts, U.S.), Integrated DNA Technologies, Inc., CENTOGENE N.V. (Rostock, Germany), Merit Medical Systems(Utah, U.S.), Invitae Corporation (California, U.S.), PerkinElmer Inc.(Massachusetts, U.S.), QIAGEN (California, U.S.), and GeneDx, LLC(Connecticut, U.S) among others. |
Market Definition
Cancer begins in the lymphs and most often occurs in people who smoke. Two major types of non-Hodgkin lymphoma are aggressive non-Hodgkin lymphoma and indolent non-Hodgkin lymphoma. Causes of non-Hodgkin lymphoma include smoking, second-hand smoke, exposure to certain toxins, and family history.
Symptoms include a cough (often with blood), chest pain, wheezing, and weight loss. These symptoms often don't appear until the cancer is advanced. Treatments vary but may include surgery, chemotherapy, radiation therapy, targeted drug therapy, and immunotherapy.
North America Non-Hodgkin Lymphoma Diagnostics Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints and challenges. All of this is discussed in detail as below:
- Increased Growth in Prevalence of Non-Hodgkin Lymphoma
Lymphoma is the general name for many related subtypes of cancer that arise from a type of white blood cell called a “lymphocyte.” Lymphoma is divided into two major categories Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphoma (NHL). Non-Hodgkin's lymphoma is a general category of lymphoma. There are many subtypes that fall into this category. Diffuse large B cell lymphoma and follicular lymphoma are among the most common subtypes. Lymphoma cancer cases are rising worldwide. Non-Hodgkin Lymphoma (NHL) is one of the most common cancers in the United States, accounting for about 4% of all cancers.
The chance that a man will develop NHL in his lifetime is about 1 in 43; for a woman, the risk is about 1 in 53. In 2020, as per the International Agency for Research on Cancer by World Health Organization (WHO), there were an estimated 544,352 people found to be diagnosed with non-Hodgkin lymphoma worldwide.
- Increase in Awareness Regarding Non-Hodgkin Lymphoma
The non-Hodgkin lymphoma awareness is a chance to increase knowledge about these diseases and to spotlight research into their causes, prevention, diagnosis, treatment, and survival. The objective is to assist persons who have been impacted by lymphoma and to promote healthy habits.
The fifth most prevalent cancer in the world is lymphoma. As per the report by World Health Organization, Asia has the highest incidence rate of 241,270 patients for the past 5 years. Also, non-Hodgkin lymphoma accounts for 7.4% of all cancer deaths in Asia. The death rate has very slowly increased each year.
Every year, several awareness campaigns, webinars, and conferences are planned around the globe to educate people about non-Hodgkin lymphoma, and various organizations take the lead in these campaigns. As a result, this is expected to drive the growth of the North America non-Hodgkin lymphoma diagnostics market.
- Lack of Availability of Trained and Skilled Medical Professionals
The density of the total health workforce is estimated to be 29 per 10,000 population but only 16 per 10,000 for trained workers. The requirement for skilled and certified professionals is a big restraint for the North America non-Hodgkin lymphoma diagnostics market. The demand for fluorescent in situ hybridization is increased due to increasing cases of cancer diseases and genetic anomalies, but the less number of skilled professionals present is expected to hamper the growth of the market.
The ability of a qualified medical practitioner to conduct numerous tests is crucial to the growth of the healthcare and medical sectors. The main goal of having a professional team is to guarantee that every piece of life-saving medical equipment will function effectively when it is most needed. The technician needs to have the appropriate education and certification from the relevant manufacturers and authorities.
Technicians face technical training gaps related to problems adapting advanced methods safely to perform procedures efficiently. For the diagnosis of lymphoma, there is a high need for skilled professionals for method development, validation, operation, and troubleshooting activities
- Stringent Regulations and Guidelines for Different Treatments and Diagnosis
Selling medical devices or medications in such jurisdictions can entail substantial financial expenditure, which could take months or years to complete. If these constraints are not understood or considered, delays can seriously jeopardize the likelihood of success in a highly competitive market. But their approval and marketing in multiple regions across the globe require meeting stringent regulatory standards and acceptance by various regulatory bodies.
The companies must carefully review the product specifications before categorizing them according to the Food and Drug Administration (FDA) protocols. Setting up drug discovery and development programs in academic, non-profit, and other life science research companies requires careful planning. Every country has its own regulatory body, and regulatory agencies have minimal oversight of drug discovery studies yet provide certain requirements and clear documentation to achieve milestones during this process. The regulatory framework aims to improve access for better quality and provide guidance on strengthening regulatory controls.
Post COVID-19 Impact on North America Non-Hodgkin Lymphoma Diagnostics Market
The high burden of COVID-19 on health-care systems around the world has raised concerns among medical oncologists about the impact of COVID-19 on non-Hodgkin lymphoma diagnosis and treatment. We investigated the impact of COVID-19 on non-Hodgkin lymphoma diagnosis and treatment before and after the COVID-19 era in this retrospective cohort study. During the pandemic, new non-Hodgkin lymphoma diagnoses decreased with slightly more advanced stages of the disease, and there was a significant increase in radiosurgery as the first definitive treatment and a decrease in both systemic treatment and surgery compared to the pre-COVID-19 era. When compared to pre-COVID-19 times, there was no significant delay in starting chemotherapy and radiation treatment during the pandemic.
During the pandemic, however, we observed a delay in non-Hodgkin lymphoma surgery. COVID-19 appears to have had a significant impact on non-Hodgkin lymphoma patients' diagnoses and treatment patterns at our non-Hodgkin lymphoma center. Many oncologists are concerned that the number of newly diagnosed non-hodgkin lymphoma patients will rise in the coming year. This research is still ongoing, and more information will be gathered and analyzed to better understand the overall impact of the COVID-19 pandemic on our non-Hodgkin lymphoma patient population.
Recent Development
- In November 2022, Danaher. announced that it had entered a strategic partnership with Duke University to form its first Danaher Beacon for Gene Therapy Innovation. The program invests in product innovation to advance external R&D strategies with a focus on genomic medicines, precision diagnostics, next generation biomanufacturing, human systems, and data sciences.
- In August 2022, Bio-Rad Laboratories Inc. acquired Curiosity Diagnostics, a Poland-based developer of innovative technology solutions for the medical diagnostic and healthcare markets. This has helped the company to increase its product portfolio and North America presence in the market.
North America Non-Hodgkin Lymphoma Diagnostics Market Segmentation
The North America non-Hodgkin lymphoma diagnostics market is categorized into eight notable segments, which are based on the test type, cancer stage, tumor type, product, technology, application, end users, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
BY TEST TYPE
- Imaging
- Biopsy
- Immunohistochemistry
- Biomarker Test
- Genetic Test
- Cytogenetics
- Lumbar Puncture (Spinal Tap)
- Blood Test
- Cytochemistry
- Others
BY CANCER STAGE
- Stage 0
- Stage I
- Stage II
- Stage III
- Stage IV
BY TUMOR TYPE
- Aggressive Lymphomas
- Indolent Lymphomas
BY PRODUCT
- Instrument Based Products
- Platform Based Products
- Kits And Reagents
- Other Consumables
BY TECHNOLOGY
- Fluorescent In Situ Hybridization
- Next Generation Sequencing
- Fluorimmunoassay
- Comparative Genomic Hybridization
- Immunohistochemical
- Others
BY APPLICATION
- Screening
- Diagnostic And Predictive
- Prognostic
- Research
BY END USER
- Hospitals
- Diagnostic Centers
- Cancer Research Centers
- Academic Institutes
- Ambulatory Surgical Centers
- Others
BY DISTRIBUTION CHANNEL
- Direct Tender
- Retail Sales
- Others
North America Non-Hodgkin Lymphoma Diagnostics Market Regional Analysis/Insights
The North America non-Hodgkin lymphoma diagnostics market is analysed, and market size insights and trends are provided by test type, cancer stage, tumor type, product, technology, application, end user, distribution channel as referenced above.
The countries covered in the non-Hodgkin lymphoma diagnostics report are the U.S., Canada, Mexico,
U.S is dominating the North America non-Hodgkin lymphoma diagnostics market. The increasing research in the field of non-Hodgkin lymphoma diagnosis and development is further boosting the North America market growth. The U.S. dominates the North America region due to exponential awareness of cancer diagnostics and consultancy services in the country.
La section par pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces du porteur, ainsi que des études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques nord-américaines et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et des routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché du diagnostic du lymphome non hodgkinien en Amérique du Nord
Le paysage concurrentiel du marché du diagnostic du lymphome non hodgkinien en Amérique du Nord fournit des détails par concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence en Amérique du Nord, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises sur le marché du diagnostic du lymphome non hodgkinien.
Certains des principaux acteurs opérant sur le marché sont CANON MEDICAL SYSTEMS CORPORATION, Koninklijke Philips NV, Siemens Healthcare GmbH, Danaher., Bio-Rad Laboratories, Inc., General Electric Company, Sysmex Corporation, Grail, F. Hoffmann-La Roche, Neusoft Corporation, Agilent Technologies, Inc., NeoGenomics Laboratories, Hologic, Inc, Integrated DNA Technologies, Inc., CENTOGENE NV, Merit Medical Systems, Invitae Corporation, PerkinElmer Inc., QIAGEN et GeneDx, LLC, entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S 5 FORCES
5 INDUSTRY INSIGHTS
6 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASED GROWTH IN PREVALENCE OF NON-HODGKIN LYMPHOMA
7.1.2 INCREASE IN AWARENESS REGARDING NON-HODGKIN LYMPHOMA
7.1.3 ADVANCEMENT IN ARTIFICIAL INTELLIGENCE IN DIAGNOSIS OF NON-HODGKIN LYMPHOMA
7.1.4 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UP
7.2 RESTRAINTS
7.2.1 LACK OF AVAILABILITY OF TRAINED AND SKILLED MEDICAL PROFESSIONALS
7.2.2 STRINGENT REGULATIONS AND GUIDELINES FOR DIFFERENT TREATMENTS AND DIAGNOSIS
7.3 OPPORTUNITIES
7.3.1 TECHNICAL ADVANCEMENTS IN CANCER DIAGNOSIS
7.3.2 INCREASING HEALTHCARE EXPENDITURE IN CANCER R&D
7.3.3 GROWING INITIATIVES BY GOVERNMENT AND KEY PLAYERS
7.4 CHALLENGES
7.4.1 LACK OF EARLY DIAGNOSTIC AWARENESS AMONG PEOPLE
7.4.2 HIGH DIAGNOSTIC COST AND FEAR OF TREATMENT
7.4.3 COMMON MISDIAGNOSIS OF NON-HODGKIN LYMPHOMA (NHL)
8 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TEST TYPE
8.1 OVERVIEW
8.2 IMAGING
8.2.1 COMPUTED TOMOGRAPHY (CT)
8.2.2 CHEST X-RAY
8.2.3 MAGNETIC RESONANCE IMAGING (MRI)
8.2.4 ULTRASOUND
8.2.5 POSITRON EMISSION TOMOGRAPHY (PET)
8.3 BIOPSY
8.3.1 EXCISIONAL OR INCISIONAL BIOPSY
8.3.2 CORE NEEDLE BIOPSY
8.4 IMMUNOHISTOCHEMISTRY
8.5 BIOMARKER TEST
8.5.1 BETA 2-M
8.5.2 LDH
8.5.3 CA-125
8.5.4 TP53
8.5.5 NPM1
8.5.6 OTHERS
8.6 GENETIC TEST
8.7 CYTOGENETICS
8.8 LUMBAR PUNCTURE (SPINAL TAP)
8.9 BLOOD TEST
8.1 CYTOCHEMISTRY
8.11 OTHERS
9 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TUMOR TYPE
9.1 OVERVIEW
9.2 AGGRESSIVE LYMPHOMAS
9.2.1 DIFFUSE LARGE B CELL LYMPHOMA
9.2.1.1 INSTRUMENT BASED PRODUCTS
9.2.1.2 PLATFORM BASED PRODUCTS
9.2.1.3 KITS AND REAGENTS
9.2.1.4 OTHER CONSUMABLES
9.2.2 ANAPLASTIC LARGE-CELL LYMPHOMA
9.2.2.1 INSTRUMENT BASED PRODUCTS
9.2.2.2 PLATFORM BASED PRODUCTS
9.2.2.3 KITS AND REAGENTS
9.2.2.4 OTHER CONSUMABLES
9.2.3 MANTLE CELL LYMPHOMA
9.2.3.1 INSTRUMENT BASED PRODUCTS
9.2.3.2 PLATFORM BASED PRODUCTS
9.2.3.3 KITS AND REAGENTS
9.2.3.4 OTHER CONSUMABLES
9.2.4 PERIPHERAL T-CELL LYMPHOMA
9.2.4.1 INSTRUMENT BASED PRODUCTS
9.2.4.2 PLATFORM BASED PRODUCTS
9.2.4.3 KITS AND REAGENTS
9.2.4.4 OTHER CONSUMABLES
9.2.5 LYMPHOBLASTIC LYMPHOMA
9.2.5.1 INSTRUMENT BASED PRODUCTS
9.2.5.2 PLATFORM BASED PRODUCTS
9.2.5.3 KITS AND REAGENTS
9.2.5.4 OTHER CONSUMABLES
9.2.6 BURKITT LYMPHOMA
9.2.6.1 INSTRUMENT BASED PRODUCTS
9.2.6.2 PLATFORM BASED PRODUCTS
9.2.6.3 KITS AND REAGENTS
9.2.6.4 OTHER CONSUMABLES
9.3 INDOLENT LYMPHOMAS
9.3.1 FOLLICULAR LYMPHOMA
9.3.1.1 INSTRUMENT BASED PRODUCTS
9.3.1.2 PLATFORM BASED PRODUCTS
9.3.1.3 KITS AND REAGENTS
9.3.1.4 OTHER CONSUMABLES
9.3.2 CUTANEOUS T-CELL LYMPHOMA
9.3.2.1 INSTRUMENT BASED PRODUCTS
9.3.2.2 PLATFORM BASED PRODUCTS
9.3.2.3 KITS AND REAGENTS
9.3.2.4 OTHER CONSUMABLES
9.3.3 MARGINAL ZONE B CELL LYMPHOMA
9.3.3.1 INSTRUMENT BASED PRODUCTS
9.3.3.2 PLATFORM BASED PRODUCTS
9.3.3.3 KITS AND REAGENTS
9.3.3.4 OTHER CONSUMABLES
9.3.4 LYMPHOPLASMACYTIC LYMPHOMA
9.3.4.1 INSTRUMENT BASED PRODUCTS
9.3.4.2 PLATFORM BASED PRODUCTS
9.3.4.3 KITS AND REAGENTS
9.3.4.4 OTHER CONSUMABLES
9.3.5 SMALL-CELL LYMPHOCYTIC LYMPHOMA
9.3.5.1 INSTRUMENT BASED PRODUCTS
9.3.5.2 PLATFORM BASED PRODUCTS
9.3.5.3 KITS AND REAGENTS
9.3.5.4 OTHER CONSUMABLES
10 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 SCREENING
10.2.1 INSTRUMENT BASED PRODUCTS
10.2.2 PLATFORM BASED PRODUCTS
10.2.3 KITS AND REAGENTS
10.2.4 OTHER CONSUMABLES
10.3 DIAGNOSTIC AND PREDICTIVE
10.3.1 INSTRUMENT BASED PRODUCTS
10.3.2 PLATFORM BASED PRODUCTS
10.3.3 KITS AND REAGENTS
10.3.4 OTHER CONSUMABLES
10.4 PROGNOSTIC
10.4.1 INSTRUMENT BASED PRODUCTS
10.4.2 PLATFORM BASED PRODUCTS
10.4.3 KITS AND REAGENTS
10.4.4 OTHER CONSUMABLES
10.5 RESEARCH
10.5.1 INSTRUMENT BASED PRODUCTS
10.5.2 PLATFORM BASED PRODUCTS
10.5.3 KITS AND REAGENTS
10.5.4 OTHER CONSUMABLES
11 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE
11.1 OVERVIEW
11.2 STAGE IV
11.3 STAGE I
11.4 STAGE III
11.5 STAGE II
11.6 STAGE 0
12 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TECHNOLOGY
12.1 OVERVIEW
12.2 FLUORESCENT IN SITU HYBRIDIZATION
12.3 NEXT GENERATION SEQUENCING
12.4 FLUORIMMUNOASSAY
12.5 COMPARATIVE GENOMIC HYBRIDIZATION
12.6 IMMUNOHISTOLOCHEMICAL
12.7 OTHER
13 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY PRODUCT
13.1 OVERVIEW
13.2 INSTRUMENT BASED PRODUCTS
13.2.1 IMAGING
13.2.2 BIOPSY
13.3 PLATFORM BASED PRODUCTS
13.3.1 NEXT-GENERATION SEQUENCING
13.3.2 MICROARRAYS
13.3.3 PCR
13.3.4 OTHERS
13.4 KITS AND REAGENTS
13.4.1 NON-HODGKIN LYMPHOMA PANELS
13.4.2 IMMUNOHISTOCHEMISTRY STAINS
13.4.3 OTHERS
13.5 OTHER CONSUMABLES
14 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 DIAGNOSTIC CENTERS
14.4 CANCER RESEARCH CENTERS
14.5 ACADEMIC INSTITUTES
14.6 AMBULATORY SURGICAL CENTERS
14.7 OTHERS
15 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 RETAIL SALES
15.4 OTHERS
16 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 SWOT ANALYSIS
19 NORTH AMERICA NON-HODKIN LYMPHOMA DIAGNOSTICS MARKET
19.1 CANON MEDICAL SYSTEMS CORPORATION
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENT
19.2 KONINKLIJKE PHILIPS N.V.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 SIEMENS HEALTHCARE GMBH
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 DANAHER.
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 BIO-RAD LABORATORIES, INC.
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENT
19.6 AGILENT TECHNOLOGIES, INC.
19.6.1 COMPANY PROFILE
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 CENTOGENE N.V.
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 F. HOFFMANN- LA ROCHE LTD
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 GENERAL ELECTRIC COMPANY
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENTS
19.1 GENEDX, LLC
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 GRAIL
19.11.1 COMPANY PROFILE
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENT
19.12 HOLOGIC INC.
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENT
19.13 INVITAE CORPORATION
19.13.1 COMPANY PROFILE
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENT
19.14 NEUSOFT CORPORATION
19.14.1 COMPANY SNAPSHOT
19.14.2 REVENUE ANALYSIS
19.14.3 PRODUCT PORTFOLIO
19.14.4 RECENT DEVELOPMENT
19.15 NEOGENOMICS LABORATORIES
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENTS
19.16 PERKINELMER INC
19.16.1 COMPANY PROFILE
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENT
19.17 QIAGEN
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENT
19.18 SYSMEX CORPORATION
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
Liste des tableaux
TABLE 1 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 2 NORTH AMERICA IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 3 NORTH AMERICA IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 4 NORTH AMERICA BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 6 NORTH AMERICA IMMUNOHISTOCHEMISTRY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 NORTH AMERICA BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA GENETIC TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA CYTOGENETICS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA LUMBAR PUNCTURE (SPINAL TAP) IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 NORTH AMERICA BLOOD TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA CYTOCHEMISTRY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 36 NORTH AMERICA PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 NORTH AMERICA PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 38 NORTH AMERICA RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 NORTH AMERICA RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 40 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 41 NORTH AMERICA STAGE IV IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 NORTH AMERICA STAGE I IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 NORTH AMERICA STAGE III IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 NORTH AMERICA STAGE II IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION
TABLE 45 NORTH AMERICA STAGE 0 IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 47 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 NORTH AMERICA NEXT GENERATION SEQUENCING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 49 NORTH AMERICA FLUORIMMUNOASSAY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 NORTH AMERICA COMPARATIVE GENOMIC HYBRIDIZATION IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 NORTH AMERICA IMMUNOHISTOCHEMICAL IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 NORTH AMERICA OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 54 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 56 NORTH AMERICA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 NORTH AMERICA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 58 NORTH AMERICA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 59 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 60 NORTH AMERICA OTHER CONSUMABLES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION))
TABLE 61 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 62 NORTH AMERICA HOSPITALS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 63 NORTH AMERICA DIAGNOSTIC CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 64 NORTH AMERICA CANCER RESEARCH CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 65 NORTH AMERICA ACADEMIC INSTITUTES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 66 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 67 NORTH AMERICA OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 68 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 69 NORTH AMERICA DIRECT TENDER IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 70 NORTH AMERICA RETAIL SALES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 71 NORTH AMERICA OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 72 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 73 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 74 NORTH AMERICA IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 75 NORTH AMERICA BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 76 NORTH AMERICA BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 77 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 78 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 79 NORTH AMERICA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 80 NORTH AMERICA DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 81 NORTH AMERICA ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 82 NORTH AMERICA MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 83 NORTH AMERICA PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 84 NORTH AMERICA LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 85 NORTH AMERICA BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 86 NORTH AMERICA INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 87 NORTH AMERICA FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 88 NORTH AMERICA CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 89 NORTH AMERICA MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 90 NORTH AMERICA LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 91 NORTH AMERICA SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 92 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 93 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 94 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 95 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 96 NORTH AMERICA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 97 NORTH AMERICA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 98 NORTH AMERICA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 99 NORTH AMERICA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 100 NORTH AMERICA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 101 NORTH AMERICA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 102 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 103 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 104 NORTH AMERICA SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 105 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 106 NORTH AMERICA PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 107 NORTH AMERICA RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 108 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 109 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 110 U.S. NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 111 U.S. IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 112 U.S. BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 113 U.S. BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 114 U.S. NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 115 U.S. NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 116 U.S. AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 117 U.S. DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 118 U.S. ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 119 U.S. MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 120 U.S. PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 121 U.S. LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 122 U.S. BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 123 U.S. INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 124 U.S. FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 125 U.S. CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 126 U.S. MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 127 U.S. LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 128 U.S. SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 129 U.S. NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 130 U.S. INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 131 U.S. INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 132 U.S. INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 133 U.S. PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 134 U.S. PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 135 U.S. PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 136 U.S. KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 137 U.S. KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 138 U.S. KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 139 U.S. NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 140 U.S. NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 141 U.S. SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 142 U.S. DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 143 U.S. PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 144 U.S. RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 145 U.S. NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 146 U.S. NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 147 CANADA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 148 CANADA IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 149 CANADA BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 150 CANADA BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 151 CANADA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 152 CANADA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 153 CANADA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 154 CANADA DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 155 CANADA ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 156 CANADA MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 157 CANADA PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 158 CANADA LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 159 CANADA BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 160 CANADA INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 161 CANADA FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 162 CANADA CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 163 CANADA MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 164 CANADA LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 165 CANADA SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 166 CANADA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 167 CANADA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 168 CANADA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 169 CANADA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 170 CANADA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 171 CANADA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 172 CANADA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 173 CANADA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 174 CANADA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 175 CANADA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 176 CANADA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 177 CANADA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 178 CANADA SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 179 CANADA DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 180 CANADA PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 181 CANADA RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 182 CANADA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 183 CANADA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 184 MEXICO NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 185 MEXICO IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 186 MEXICO BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 187 MEXICO BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 188 MEXICO NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 189 MEXICO NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 190 MEXICO AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 191 MEXICO DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 192 MEXICO ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 193 MEXICO MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 194 MEXICO PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 195 MEXICO LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 196 MEXICO BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 197 MEXICO INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 198 MEXICO FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 199 MEXICO CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 200 MEXICO MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 201 MEXICO LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 202 MEXICO SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 203 MEXICO NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 204 MEXICO INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 205 MEXICO INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 206 MEXICO INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 207 MEXICO PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 208 MEXICO PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 209 MEXICO PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 210 MEXICO KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 211 MEXICO KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 212 MEXICO KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 213 MEXICO NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 214 MEXICO NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 215 MEXICO SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 216 MEXICO DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 217 MEXICO PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 218 MEXICO RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 219 MEXICO NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 220 MEXICO NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
Liste des figures
FIGURE 1 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: MULTIVARIATE MODELLING
FIGURE 7 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 10 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 12 THE INCREASING PREVALENCE OF NON-HODGKIN LYMPHOMA AND INCREASED RESEARCH & DEVELOPMENT IN NON-HODGKIN LYMPHOMA DIAGNOSTICS ARE DRIVING THE NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 13 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET
FIGURE 15 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, 2022
FIGURE 16 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 17 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 18 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 19 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, 2022
FIGURE 20 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, 2023-2030 (USD MILLION)
FIGURE 21 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, CAGR (2023-2030)
FIGURE 22 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, LIFELINE CURVE
FIGURE 23 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, 2022
FIGURE 24 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 25 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 26 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 27 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, 2022
FIGURE 28 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, 2023-2030 (USD MILLION)
FIGURE 29 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, CAGR (2023-2030)
FIGURE 30 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, LIFELINE CURVE
FIGURE 31 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, 2022
FIGURE 32 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 33 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 34 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 35 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, 2022
FIGURE 36 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, 2023-2030 (USD MILLION)
FIGURE 37 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, CAGR (2023-2030)
FIGURE 38 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 39 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, 2022
FIGURE 40 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 41 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030)
FIGURE 42 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 44 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 45 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 46 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 48 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 49 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 50 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 51 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: TEST TYPE (2023-2030)
FIGURE 52 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
